Efficacy and safety of testosterone drugs in the treatment of hypogonadism in men


Cite item

Full Text

Abstract

The article presents current state of hypogonadism problem, in particular its age forms; the role of the hypogonadism in the development of sexual function disorders in men is presented. We discuss the relationship of hypogonadism with somatic disorders, including cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. We consider testosterone drugs that currently use for the treatment of hypogonadism and erectile dysfunction. We particularly discuss the problem of hormonal replacement therapy safety using testosterone drugs, particularly its impact on the risk of prostate cancer development.

References

  1. Ferrini RL, Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998;147:750-54.
  2. Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997;11:289-309.
  3. Morley JE, Kaiser FE, Perry HM, et al. Long itudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-13.
  4. Vermeulen A, Kaufman JM, Goemaere S, et al. Estradiol in elderly men. Aging Male 2002;5(2):98-102.
  5. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.
  6. Gray A, Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-25.
  7. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res 2003;15(Suppl. 4):S14-20.
  8. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogo-nadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-68.
  9. Guay AT, Velasquez E, Perez JB. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 1999;5:314-21.
  10. Hatzichristou D, Hatzimouratidis K, Bekas M, et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002;168:615-20.
  11. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: Its relation to impotence. J Clin Endocrinol Metab 1990;71:963-69.
  12. Shabsigh R. Hypogonadism and erectile dysfunction: The role for testosterone therapy. Int J Impot Res 2003;15(Suppl. 4):S9-S13.
  13. Aversa A, Bruzziches R, Greco EA, et al. Possible involvement of gonadic steroids in determining erectile response to pharmacoerection test in men with erectile dysfunction. It J Sex Reprod Med 2006;13:3-9.
  14. Morley JE. Impotence. Am J Med 1986;80:897-905.
  15. Малколм Каррузерс. Революция тестостерона. М., 2005. 224 c.
  16. Brown-Sequard CE. Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 1889;2:105-07.
  17. David K, Dingemanse E, Freud J, et al. Uber krystallinisches mannliches Hormon aus Hoden (Testosteron), wirksamer als aus Harn oder aus Cholesterin bereitetes Androsteron. Hoppe Seyler Z Physiol Chem 1935;233:281-82.
  18. Butenandt FJ, Hanish G. Uber Testosteron. Umwanlung des Dehydroandrosterons in Androstendiol und Testosteron: ein Weg zur Darstellung desTestosterons aus Cholesterin Hoppe- Seylers. Z Angew Chem 1935;237:89-98.
  19. Ruzicka L, Wettstein A. Synthetische Darstellung der Testishhormons, Testosteron (Androsten 3 on 17-ol). Helv Chim Acta 1935;18:1264-75.
  20. Mooradian AD, Morey JE, Korenman SG. Biological actions of androgens. Endocrinol Rev 1987;8:1-28.
  21. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
  22. Aversa A, Bruzziches R, Spera G. A rationale for the use on testosterone "salvage" in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors. Endocrinologist 2005;15:99-105.
  23. Traish AM, Toselli P, Jeong SJ, et al. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for venoocclusive dysfunction in androgen deficiency. J Androl 2005;26:242-48.
  24. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005;2:759-70.
  25. Zhang XH, Filippi S, Morelli A, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006;3:253-64.
  26. Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-68.
  27. Moreno S, et al. ESSM Today 2009;17:5(#778).
  28. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727-35.
  29. Hatzimouradis K, Hatzichristou D. Testosterone and erectile function: an unresolved enigma. Eur Urol 2007;52:26-28.
  30. Meusburger SM, Keast JR. Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 2001;108:331-40.
  31. Rogers RS, Graziottin TM, Lin CM, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-assoicated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37.
  32. Aversa A, Isidori AM, De Martino MU. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilatation in men with erectile dysfunction. Clin Endocrinol 2000;53:517-22.
  33. Van den Beld AW, Bots ML, Janssen JA, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003;157:25-31.
  34. Chou TM, Sudhir K, Hutchison SJ, et al. Circulation 1996;94:2614-19.
  35. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666-70.
  36. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-47.
  37. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
  38. Wynne FL, Khalil RA. J Endocrinol Invest 2003;26:181-86.
  39. Svartberg J. Should men be treated with testosterone? Tidsskr Nor Laegeforen 2005;125(7):879-82.
  40. Gooren L. Visceral obesity, metabolic syndrome, androgens and estrogens. Aging Male 2006;9(2):75-79.
  41. Rosano GM. Androgens and coronary artery disease. A sex-specific effect of sex hormones? Eur Heart J 2000;21:868-71.
  42. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24(3):313-40.
  43. Siu SC, Lo SK, Wong KW, et al. Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med 2001;18:732-38.
  44. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23(4):490-94.
  45. Mao JF, Wu XY, Li NS, et al. Testosterone replacement in hypogonadotropic hypogonadal young male improves insulin sensitivity. Zhonghua Yi Xue Za Zhi 2008;88(36):2550-52.
  46. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004;89(10):4863-72.
  47. Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003;148(l):55-66.
  48. Pritchard J, Despres JP, Gagnon J, et al. Plasma adrenal, gonadal, and conjugated steroids before and after long-term overfeeding in identical twins. J Clin Endocrinol Metab 1998;83(9):3277-84.
  49. Gooren L. Visceral obesity, metabolic syndrome, androgens and estrogens. Aging Male 2006;9(2):75-79.
  50. Kapoor D, Malkin CJ, Channer KS, et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63(3):239-50.
  51. Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827-34.
  52. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82(2):407-113.
  53. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypohonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85:2839-53.
  54. Kupelian V, Shabsigh R, Araujo AB, et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006;176:222-26.
  55. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes in middle- aged men. Diabetes Care 2004;27:1036-41.
  56. Haider A, et al. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009;41(1):7-13.
  57. Kalinchenko SY, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11(2):57-61.
  58. Takao T, et al. Lower urinary tract symptoms after hormone replacement therapy in Japanese patients with late-onset hypogonadism: a preliminary report. Int J Urol 2009;16(2):212-14.
  59. Conaglen J, et al. J Sex Med 2009;6:456-63.
  60. Nieschlag E, Behre HM. Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. 2nd ed. Berlin-Heidelberg: Springer-Verlag 1998:293-328.
  61. Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. Front Horm Res 2009;37:5-20.
  62. Bhasin S, Cunningham GR. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2007;92(2):418-19.
  63. Mattern C, et al. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 2008;11(4):171-78.
  64. Morgentaler A, et al. J Urol 2008;180(6):2307-13.
  65. Tenover JL. Male hormone replacement therapy including "andropause". Endocrinol Metab Clin North Am 1998;27:969-87.
  66. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001;110:563-72.
  67. Marks LS, Mazer NA, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Eur Urol 2007;52(1):284-85.
  68. Coward RM, et al. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009;103(9):1179-83.
  69. Raynaud JP. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol 2009;114(1-2):96-105.
  70. Rinnab L, Gust K, Hautmann RE, et al. Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth. Urologe A 2009;48(5):516-22.
  71. Khera M, et al. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009;6(Suppl. 3):234-38.
  72. Khera MA, et al. J Sex Med 2009; 6 (Suppl 1): 24.
  73. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009;103(1):62-64.
  74. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109(3):536-41.
  75. Morgentaler A, et al. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med 2009;6(2):574-77.
  76. Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155:1604-08.
  77. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf). 1999;50:57-62.
  78. Edelstain D, Sivanandy M, Shahani S, et al. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007;8(17):2991-3008.
  79. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2421&mid=1085056570&magid=180

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies